CSIMarket
 


Trevena inc   (TRVN)
Other Ticker:  
 

Cumulative Trevena Inc 's Quick Ratio for Trailing Twelve Months Period

TRVN's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

TRVN Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -33.5 % -14.02 % -10.16 % 4.03 % 39.27 %
Y / Y Cash & cash equivalent Growth -13.47 % -43.26 % -43.62 % -42.74 % -48.64 %
Quick Ratio for Trailing Twelve Months Period 4.14 3.93 4.38 4.86 5.69
Total Ranking # 566 # 659 # 671 # 721 # 648
Seq. Current Liabilities Growth -24.71 % 1.96 % -8.17 % -5.67 % -2.65 %
Seq. Cash & cash equivalent Growth 24.4 % 2.41 % -28.4 % -5.13 % -18.44 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Current Liabilities decreased faster than Trevena Inc 's average Cash & cash equivalent, this led to increase in in Trevena Inc 's Quick Ratio for Trailing Twelve Months Period to 4.14, Quick Ratio for Trailing Twelve Months Period remained below Trevena inc average.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 175 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Trevena Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about TRVN
Quick Ratio TRVN in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 176
Sector # 296
S&P 500 # 413


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
12.77 6.28 3.46
(Sep 30 2016)   (Sep 30 2019)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Dianthus Therapeutics Inc   11.39 
Cytokinetics Incorporated  11.36 
Trevi Therapeutics Inc   11.34 
Prothena Corporation Public Limited Company  11.24 
Annexon Inc   11.21 
An2 Therapeutics Inc   11.15 
Erasca Inc   11.12 
Reneo Pharmaceuticals Inc   11.07 
Milestone Pharmaceuticals inc   11.06 
Acasti Pharma Inc   10.98 
Sage Therapeutics Inc   10.78 
Biomea Fusion Inc   10.74 
Relmada Therapeutics Inc   10.64 
Cogent Biosciences Inc   10.43 
Sinovac Biotech Ltd  10.37 
Point Biopharma Global Inc   10.33 
Kalvista Pharmaceuticals Inc   10.31 
Rocket Pharmaceuticals Inc   10.26 
Kronos Bio Inc   10.11 
Shuttle Pharmaceuticals Holdings Inc   10.06 
Pepgen Inc   9.81 
Centessa Pharmaceuticals Plc  9.79 
Landos Biopharma Inc   9.76 
Compass Pathways Plc  9.74 
Cormedix Inc   9.72 
Allakos Inc   9.66 
Lumos Pharma Inc   9.56 
Protagonist Therapeutics inc   9.51 
Mineralys Therapeutics Inc   9.49 
Igm Biosciences Inc   9.47 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com